Terms: = Skin cancer AND IL2, IL-2, 3558, ENSG00000109471, P60568 AND Prognosis
60 results:
1. Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in skin cutaneous melanoma.
Zhang W; Wang S
Melanoma Res; 2024 Jun; 34(3):215-224. PubMed ID: 38364052
[TBL] [Abstract] [Full Text] [Related]
2. Correlations between inflammatory cytokine levels and degree of pigmentation in acral melanomas.
Kim HE; Kim J; Park HK; Lee JB; Yun SJ
Melanoma Res; 2024 Feb; 34(1):38-43. PubMed ID: 37924528
[TBL] [Abstract] [Full Text] [Related]
3. Pyroptosis relates to tumor microenvironment remodeling and prognosis: A pan-cancer perspective.
Khan M; Ai M; Du K; Song J; Wang B; Lin J; Ren A; Chen C; Huang Z; Qiu W; Zhang J; Tian Y; Yuan Y
Front Immunol; 2022; 13():1062225. PubMed ID: 36605187
[TBL] [Abstract] [Full Text] [Related]
4. Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?
Ziogas DC; Theocharopoulos C; Koutouratsas T; Haanen J; Gogas H
Cancer Treat Rev; 2023 Feb; 113():102499. PubMed ID: 36542945
[TBL] [Abstract] [Full Text] [Related]
5. Serum cell-free DNA as a new biomarker in cutaneous T-cell lymphoma.
Mizuno Y; Shibata S; Miyagaki T; Ito Y; Taira H; Omori I; Hisamoto T; Oka K; Matsuda KM; Boki H; Takahashi-Shishido N; Sugaya M; Sato S
J Dermatol; 2022 Nov; 49(11):1124-1130. PubMed ID: 35821652
[TBL] [Abstract] [Full Text] [Related]
6. Tumor-associated Tregs obstruct antitumor immunity by promoting T cell dysfunction and restricting clonal diversity in tumor-infiltrating CD8+ T cells.
Noyes D; Bag A; Oseni S; Semidey-Hurtado J; Cen L; Sarnaik AA; Sondak VK; Adeegbe D
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35618289
[TBL] [Abstract] [Full Text] [Related]
7. Genetically Driven CD39 Expression Affects Sezary Cell Viability and il-2 Production and Detects Two Patient Subsets with Distinct prognosis.
Picozza M; Cristofoletti C; Bresin A; Fioretti M; Sambucci M; Scala E; Monopoli A; Cantonetti M; Pilla MA; Accetturi MP; Borsellino G; D'Atri S; Caprini E; Russo G; Narducci MG
J Invest Dermatol; 2022 Nov; 142(11):3009-3019.e9. PubMed ID: 35533722
[TBL] [Abstract] [Full Text] [Related]
8. Targeting the il-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922).
Moschos SJ; Eroglu Z; Khushalani NI; Kendra KL; Ansstas G; In GK; Wang P; Liu G; Collichio FA; Googe PB; Carson CC; McKinnon K; Wang HH; Nikolaishvilli-Feinberg N; Ivanova A; Arrowood CC; Garrett-Mead N; Conway KC; Edmiston SN; Ollila DW; Serody JS; Thomas NE; Ivy SP; Agrawal L; Dees EC; Abbruzzese JL
Melanoma Res; 2021 Apr; 31(2):162-172. PubMed ID: 33661190
[TBL] [Abstract] [Full Text] [Related]
9. Staphylococcus aureus enterotoxins induce FOXP3 in neoplastic T cells in Sézary syndrome.
Willerslev-Olsen A; Buus TB; Nastasi C; Blümel E; Gluud M; Bonefeld CM; Geisler C; Lindahl LM; Vermeer M; Wasik MA; Iversen L; Becker JC; Andersen MH; Gjerdrum LMR; Litvinov IV; Litman T; Krejsgaard T; Woetmann A; Ødum N
Blood Cancer J; 2020 May; 10(5):57. PubMed ID: 32409671
[TBL] [Abstract] [Full Text] [Related]
10. PCC0208018 exerts antitumor effects by activating effector T cells.
Ge M; Hu Z; Chen X; Du G; Wang H; Liu R; Ye L; Tian J
Int J Immunopathol Pharmacol; 2019; 33():2058738419843366. PubMed ID: 30968715
[TBL] [Abstract] [Full Text] [Related]
11. Complete Clinical Remission of Stage IV Triple-Negative Breast cancer Lung Metastasis Administering Low-Dose Immune Checkpoint Blockade in Combination With Hyperthermia and Interleukin-2.
Kleef R; Moss R; Szasz AM; Bohdjalian A; Bojar H; Bakacs T
Integr Cancer Ther; 2018 Dec; 17(4):1297-1303. PubMed ID: 30193538
[TBL] [Abstract] [Full Text] [Related]
12. Immunotherapy in melanoma.
Feld E; Mitchell TC
Immunotherapy; 2018 Aug; 10(11):987-998. PubMed ID: 30149766
[TBL] [Abstract] [Full Text] [Related]
13. Current Status of Biological Therapies for the Treatment of Metastatic Melanoma.
Tang T; Eldabaje R; Yang L
Anticancer Res; 2016 Jul; 36(7):3229-41. PubMed ID: 27354579
[TBL] [Abstract] [Full Text] [Related]
14. Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab.
Valpione S; Martinoli C; Fava P; Mocellin S; Campana LG; Quaglino P; Ferrucci PF; Pigozzo J; Astrua C; Testori A; Chiarion-Sileni V
Eur J Cancer; 2015 Sep; 51(14):2086-94. PubMed ID: 26227432
[TBL] [Abstract] [Full Text] [Related]
15. Detailed protocol for administration of intralesional il-2 for the treatment of Stage IIIc and IV M1a metastatic melanoma based on current NCCN guidelines.
Patel F; Wilken R; Burrall B; Martinez S; Wells V; King B; Maverakis E
Dermatol Online J; 2014 Nov; 20(11):. PubMed ID: 25419744
[TBL] [Abstract] [Full Text] [Related]
16. Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease.
Pedersen M; Andersen R; Nørgaard P; Jacobsen S; Thielsen P; Thor Straten P; Svane IM
Cancer Immunol Immunother; 2014 Dec; 63(12):1341-6. PubMed ID: 25227926
[TBL] [Abstract] [Full Text] [Related]
17. Immunotherapy-induced leukoderma from treatment of melanoma with il-2: a case report and a review of the literature.
Gathings R; Lewallen R; Yosipovitch G
Acta Derm Venereol; 2015 Feb; 95(2):197-200. PubMed ID: 24820241
[TBL] [Abstract] [Full Text] [Related]
18. Toward prediction of immune mechanisms and design of immunotherapies in melanoma.
Tsoka S; Ainali C; Karagiannis P; Josephs DH; Saul L; Nestle FO; Karagiannis SN
Crit Rev Biomed Eng; 2012; 40(4):279-94. PubMed ID: 23140120
[TBL] [Abstract] [Full Text] [Related]
19. Effect of high-dose intravenous vitamin C on inflammation in cancer patients.
Mikirova N; Casciari J; Rogers A; Taylor P
J Transl Med; 2012 Sep; 10():189. PubMed ID: 22963460
[TBL] [Abstract] [Full Text] [Related]
20. Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma.
Hoejberg L; Bastholt L; Johansen JS; Christensen IJ; Gehl J; Schmidt H
Melanoma Res; 2012 Aug; 22(4):287-93. PubMed ID: 22617301
[TBL] [Abstract] [Full Text] [Related]
[Next]
